# **EAST Search History**

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1	("5306610").PN.	US-PGPUB; USPAT	OR	OFF	2007/06/22 17:08
L2	530	(544/251,514/267).CCLS.	US-PGPUB; USPAT	OR	OFF	2007/06/22 17:09
L3	. 12	12 and triazolopurine or pyrazolopurine and tricyclic	US-PGPUB; USPAT	OR .	ON	2007/06/22 17:09
L4	3	l2 and (triazolopurine or pyrazolopurine) and tricyclic	US-PGPUB; USPAT	OR	ON	2007/06/22 17:09

0/513699 1 hit = this case

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: SSPTAEAL1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

Welcome to STN International Web Page for STN Seminar Schedule - N. America NEWS WPIDS/WPIX enhanced with new FRAGHITSTR display format NEWS 2 MAR 15 NEWS 3 MAR 16 CASREACT coverage extended NEWS 4 MAR 20 MARPAT now updated daily NEWS 5 MAR 22 LWPI reloaded NEWS 6 MAR 30 RDISCLOSURE reloaded with enhancements APR 02 JICST-EPLUS removed from database clusters and STN NEWS 7 NEWS 8 APR 30 GENBANK reloaded and enhanced with Genome Project ID field NEWS 9 APR 30 CHEMCATS enhanced with 1.2 million new records NEWS 10 APR 30 CA/CAplus enhanced with 1870-1889 U.S. patent records NEWS 11 APR 30 INPADOC replaced by INPADOCDB on STN NEWS 12 MAY 01 New CAS web site launched NEWS 13 MAY 08 CA/CAplus Indian patent publication number format defined NEWS 14 MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display fields BIOSIS reloaded and enhanced with archival data NEWS 15 MAY 21 TOXCENTER enhanced with BIOSIS reload MAY 21 NEWS 16 CA/CAplus enhanced with additional kind codes for German MAY 21 NEWS 17 patents CA/CAplus enhanced with IPC reclassification in Japanese MAY 22 NEWS 18 patents CA/CAplus to be enhanced with pre-1967 CAS Registry Numbers NEWS 19 JUN 18 NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006. STN Operating Hours Plus Help Desk Availability NEWS HOURS NEWS LOGIN . Welcome Banner and News Items For general information regarding STN implementation of IPC 8 NEWS IPC8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 17:12:45 ON 22 JUN 2007

=> file reg
COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION

0.21

0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 17:12:51 ON 22 JUN 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 JUN 2007 HIGHEST RN 938223-21-3 DICTIONARY FILE UPDATES: 21 JUN 2007 HIGHEST RN 938223-21-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.


REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10785612.str

L1 STRUCTURE UPLOADED

=> d l1 L1 HAS NO ANSWERS L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 SAMPLE SEARCH INITIATED 17:13:09 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED -

15 TO ITERATE

100.0% PROCESSED

15 ITERATIONS

5 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:

ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS:

68 TO 532

PROJECTED ANSWERS:

5 TO 234

Ĺ2

5 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 17:13:13 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED -

304 TO ITERATE

100.0% PROCESSED

304 ITERATIONS

92 ANSWERS

SEARCH TIME: 00.00.01

L3

92 SEA SSS FUL L1.

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST

ENTRY

SESSION

172.10 172.31

FILE 'CAPLUS' ENTERED AT 17:13:16 ON 22 JUN 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Jun 2007 VOL 147 ISS 1 FILE LAST UPDATED: 21 Jun 2007 (20070621/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s 13 full

L4 1 L3.

=> d ibib abs hitstr

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

2004:740130 CAPLUS

DOCUMENT NUMBER:

141:260761

TITLE:

Preparation of pyrazolopurine-based tricyclic

compounds for the treatment of inflammatory and immune

diseases

INVENTOR(S):

Qiu, Yuping; Belema, Makonen; Yang, Xuejie; Zusi, Fred Christopher; Pitts, William J.

PATENT ASSIGNEE(S):

Bristol-Myers Squibb Company, USA PCT Int. Appl., 127 pp.

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

•	PATENT NO.					KIND DATE			APPLICATION NO.						DATE			
	_	VO 2004075846 VO 2004075846						WO 2004-US5384						20040224				
	WO	W:	AE,	AE,	AG,	AL,	AL,	AM,	AM,	•	AT,	•	•	-		-		
			CU,	CU,	CZ,	CZ,	DE,	DE,	DK,	DK,	CA, DM,	DZ,	EC,	EC,	EE,	EE,	EG,	ES,
			is,	JP,	JP,	KE,	KE,	KG,	KG,	KP,	GM, KP,	KP,	KR,	KR;	KZ,	KZ,	KZ,	LC,
			MZ,	MZ,	NΑ,	NI	•	·		·	MD,	•	•					
		RW:									SL, FI,							
				•	•	•		•	•		BF, BF,					-	-	
	US	2004				•		SN, 2004			US 2	004-	7856:	12		2	0040:	224
PRIORITY APPLN. INFO.: OTHER SOURCE(S):					US 2003-449770P P 20030225 CASREACT 141:260761; MARPAT 141:260761										225			

The title compds. I [R1 = H, alkyl, alkenyl, alkynyl, haloalkyl, etc.; R2 AB

= H, halo, CN, alkyl, alkenyl, alkynyl, etc.; R3 ,R4 = H, alkyl, alkenyl, alkynyl, haloalkyl, etc., or R3R4 together with the nitrogen atom to which they are attached to form a heterocycle; R5 = H, OH, halo, CN, alkyl, alkenyl, alkynyl, etc.] were prepared for the treatment of inflammatory and immune diseases. For example, reaction of 1-methyl-7-phenyl-4H-pyrazolo[5,1b]purin-4-one (preparation given) with cyclopropylamine yielded compound II. The compds. of this invention are active in vitro in the LPS-induced TNF $\alpha$  secretion model.

IT 754224-62-9P 754224-99-2P 754225-02-0P

754225-43-9P 754225-45-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of pyrazolopurine-based tricyclic compds. for the treatment of inflammatory and immune diseases)

RN 754224-62-9 CAPLUS

CN 1H-Pyrazolo[5,1-b]purin-4-amine, 7-[3-(aminomethyl)-4-fluorophenyl]-N-cyclopropyl-1-methyl- (9CI) (CA INDEX NAME)

$$H_2N-CH_2$$
 $F$ 
 $N$ 
 $N$ 
 $N$ 
 $N$ 
 $N$ 

RN 754224-99-2 CAPLUS

CN Benzeneacetic acid, 3-[1-methyl-4-(methylamino)-1H-pyrazolo[5,1-b]purin-7-yl]-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & \\ & & \\ \\ \text{MeO-C-CH}_2 & & \\ & &$$

RN 754225-02-0 CAPLUS

CN 1H-Pyrazolo[5,1-b]purin-4-amine, 7-[3-(aminomethyl)phenyl]-N,1-dimethyl-(9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{Me} \\ \\ \text{H}_2\text{N} - \text{CH}_2 \\ \\ & \text{N} \end{array} \begin{array}{c} \\ \text{N} \\ \\ \text{N} \end{array} \begin{array}{c} \\ \text{N} \\ \\ \text{N} \end{array} \begin{array}{c} \\ \text{N} \\ \\ \text{N} \end{array}$$

RN 754225-43-9 CAPLUS CN 1H-Pyrazolo[5,1-b]purin-4-amine, 7-(3-bromophenyl)-N,1-dimethyl- (9CI) (CA INDEX NAME)

RN 754225-45-1 CAPLUS
CN Benzonitrile, 3-[1-methyl-4-(methylamino)-1H-pyrazolo[5,1-b]purin-7-yl](9CI) (CA INDEX NAME)

IT 754224-30-1P 754224-32-3P 754224-33-4P 754224-35-6P 754224-37-8P 754224-40-3P 754224-41-4P 754224-43-6P 754224-46-9P 754224-48-1P 754224-50-5P 754224-53-8P 754224-55-0P 754224-59-4P 754224-65-2P 754224-67-4P 754224-68-5P 754224-70-9P 754224-72-1P 754224-73-2P 754224-75-4P 754224-77-6P 754224-78-7P 754224-81-2P 754224-83-4P 754224-86-7P 754224-88-9P 754224-91-4P 754224-92-5P 754224-94-7P 754224-95-8P 754224-96-9P 754224-97-0P 754224-98-1P 754225-01-9P 754225-04-2P 754225-05-3P 754225-06-4P 754225-07-5P 754225-09-7P 754225-11-1P 754225-12-2P 754225-14-4P 754225-16-6P 754225-18-8P 754225-19-9P 754225-20-2P 754225-22-4P

754225-24-6P 754225-26-8P 754225-27-9P 754225-29-1P 754225-31-5P 754225-33-7P 754225-35-9P 754225-36-0P 754225-38-2P 754225-41-7P 754225-46-2P 754225-47-3P 754225-48-4P 754225-49-5P 754225-50-8P 754225-51-9P 754225-53-1P 754225-54-2P 754225-56-4P 754225-58-6P 754225-60-0P 754225-62-2P 754225-63-3P 754225-65-5P 754225-66-6P 754225-68-8P 754225-70-2P 754225-71-3P 754225-72-4P 754225-73-5P 754225-74-6P 754225-76-8P 754225-78-0P 754225-80-4P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (preparation of pyrazolopurine-based tricyclic compds. for the treatment of inflammatory and immune diseases) RN 754224-30-1 CAPLUS 1H-Pyrazolo[5,1-b]purin-4-amine, N-cyclopropyl-1-methyl-7-phenyl- (9CI) CN (CA INDEX NAME)

RN 754224-32-3 CAPLUS
CN 1H-Pyrazolo[5,1-b]purin-4-amine, N,1-dimethyl-7-phenyl- (9CI) (CA INDEX NAME)

RN 754224-33-4 CAPLUS
CN 1H-Pyrazolo[5,1-b]purin-4-amine, 1-methyl-7-phenyl-N-[2-(1-piperidinyl)ethyl] - (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{Me} & \\ & \text{N} & \\ & \text{N} & \\ & \text{NH-CH}_2\text{-}\text{CH}_2\text{--}\text{N} \end{array}$$

RN 754224-35-6 CAPLUS CN Ethanol, 2-[(1-methyl-7-phenyl-1H-pyrazolo[5,1-b]purin-4-yl)amino]- (9CI) . (CA INDEX NAME)

RN 754224-37-8 CAPLUS
CN 1-Propanol, 3-[(1-methyl-7-phenyl-1H-pyrazolo[5,1-b]purin-4-yl)amino](9CI) (CA INDEX NAME)

RN 754224-41-4 CAPLUS

CN Glycine, N-[2-[(1-methyl-7-phenyl-1H-pyrazolo[5,1-b]purin-4-yl)amino]ethyl]- (9CI) (CA INDEX NAME)

RN 754224-43-6 CAPLUS

CN 2-Propanol, 1-[(1-methyl-7-phenyl-1H-pyrazolo[5,1-b]purin-4-yl)amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 754224-46-9 CAPLUS

CN 1H-Pyrazolo[5,1-b]purin-4-amine, N-(2-fluoroethyl)-1-methyl-7-phenyl-(9CI) (CA INDEX NAME)

RN 754224-48-1 CAPLUS

CN Acetamide, N-[2-[(1-methyl-7-phenyl-1H-pyrazolo[5,1-b]purin-4-yl)amino]ethyl]- (9CI) (CA INDEX NAME)

RN 754224-50-5 CAPLUS

CN 1H-Pyrazolo[5,1-b]purin-4-amine, N-(cyclopropylmethyl)-1-methyl-7-phenyl-(9CI) (CA INDEX NAME)

RN 754224-53-8 CAPLUS

CN Ethanaminium, N,N,N-trimethyl-2-[(1-methyl-7-phenyl-1H-pyrazolo[5,1-b]purin-4-yl)amino]-, chloride (9CI) (CA INDEX NAME)

● Cl -

RN 754224-55-0 CAPLUS CN 1H-Pyrazolo[5,1-b]purin-4-amine, 1-methyl-7-phenyl-N-(2-pyridinylmethyl)-(9CI) (CA INDEX NAME)

RN 754224-59-4 CAPLUS

CN 1H-Pyrazolo[5,1-b]purin-4-amine, 1-methyl-7-phenyl-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 754224-65-2 CAPLUS

CN Acetamide, N-[[5-[4-(cyclopropylamino)-1-methyl-1H-pyrazolo[5,1-b]purin-7-yl]-2-fluorophenyl]methyl]- (9CI) (CA INDEX NAME)

RN 754224-67-4 CAPLUS

CN Methanesulfonamide, N-[[5-[4-(cyclopropylamino)-1-methyl-1H-pyrazolo[5,1-b]purin-7-yl]-2-fluorophenyl]methyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} O \\ \parallel \\ N \end{array}$$

RN 754224-68-5 CAPLUS

CN 1H-Pyrazolo[5,1-b]purin-4-amine, N-cyclopropyl-1-methyl-7-[3- (methylsulfinyl)phenyl]- (9CI) (CA INDEX NAME)

RN 754224-70-9 CAPLUS

CN 1H-Pyrazolo[5,1-b]purin-4-amine, 7-[3-(aminomethyl)phenyl]-N-cyclopropyl-1-methyl- (9CI) (CA INDEX NAME)

$$H_2N-CH_2$$
 $N$ 
 $N$ 
 $N$ 
 $N$ 
 $N$ 

RN 754224-72-1 CAPLUS

CN Methanesulfonamide, N-[2-[5-[4-(cyclopropylamino)-1-methyl-1H-pyrazolo[5,1-b]purin-7-yl]-2-fluorophenyl]ethyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} O & \\ \parallel & \\ NH-CH_2-CH_2 \\ \parallel & \\ O & F \\ \hline \end{array}$$

RN 754224-73-2 CAPLUS

CN Acetamide, N-[2-[5-[4-(cyclopropylamino)-1-methyl-1H-pyrazolo[5,1-b]purin-7-yl]-2-fluorophenyl]ethyl]- (9CI) (CA INDEX NAME)

RN 754224-75-4 CAPLUS

CN Acetamide, N-[1-[5-[4-(cyclopropylamino)-1-methyl-1H-pyrazolo[5,1-b]purin-7-yl]-2-fluorophenyl]ethyl]- (9CI) (CA INDEX NAME)

RN 754224-77-6 CAPLUS

CN Benzeneacetic acid, 3-[4-(cyclopropylamino)-1-methyl-1H-pyrazolo[5,1-b]purin-7-yl]-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & &$$

RN 754224-78-7 CAPLUS

CN Benzeneacetic acid, 3-[4-(cyclopropylamino)-1-methyl-1H-pyrazolo[5,1-b]purin-7-yl]- (9CI) (CA INDEX NAME)

$$Me$$
 $N$ 
 $N$ 
 $N$ 
 $N$ 
 $N$ 
 $N$ 
 $N$ 
 $N$ 

RN 754224-81-2 CAPLUS

CN 1H-Pyrazolo[5,1-b]purin-4-amine, N-cyclopropyl-7-(4-fluorophenyl)-1-methyl-(9CI) (CA INDEX NAME)

RN 754224-83-4 CAPLUS

CN 1H-Pyrazolo[5,1-b]purin-4-amine, N-cyclopropyl-7-(3-fluorophenyl)-1-methyl-(9CI) (CA INDEX NAME)

RN 754224-86-7 CAPLUS

CN 1H-Pyrazolo[5,1-b]purin-4-amine, N-cyclopropyl-7-(3,5-dimethoxyphenyl)-1-methyl- (9CI) (CA INDEX NAME)

RN 754224-88-9 CAPLUS

CN 1,3-Benzenediol, 5-[4-(cyclopropylamino)-1-methyl-1H-pyrazolo[5,1-b]purin-7-yl]- (9CI) (CA INDEX NAME)

RN 754224-91-4 CAPLUS

CN Carbamic acid, [[3-[1-methyl-4-(methylamino)-1H-pyrazolo[5,1-b]purin-7-yl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 754224-92-5 CAPLUS

CN Propanamide, N-[[5-[4-(cyclopropylamino)-1-methyl-1H-pyrazolo[5,1-b]purin-7-yl]-2-fluorophenyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)

RN 754224-94-7 CAPLUS

CN Benzonitrile, 5-[4-(cyclopropylamino)-1-methyl-1H-pyrazolo[5,1-b]purin-7-yl]-2-fluoro- (9CI) (CA INDEX NAME)

RN 754224-95-8 CAPLUS

CN 1H-Pyrazolo[5,1-b]purin-4-amine, N-cyclopropyl-7-(3,5-difluorophenyl)-1-methyl- (9CI) (CA INDEX NAME)

RN 754224-96-9 CAPLUS

CN Benzenepropanoic acid, 3-[4-(cyclopropylamino)-1-methyl-1H-pyrazolo[5,1-b]purin-7-yl]- (9CI) (CA INDEX NAME)

$$Me$$
 $N$ 
 $N$ 
 $N$ 
 $N$ 
 $N$ 
 $N$ 
 $N$ 
 $N$ 
 $N$ 

RN 754224-97-0 CAPLUS

CN 2-Propanesulfonamide, N-[[5-[4-(cyclopropylamino)-1-methyl-1H-pyrazolo[5,1-b]purin-7-yl]-2-fluorophenyl]methyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} O & \\ I-Pr-S-NH-CH_2 & \\ O & \\ F & \\ N & \\ N$$

RN 754224-98-1 CAPLUS

CN Methanesulfonamide, N-[2-[3-[1-methyl-4-(methylamino)-1H-pyrazolo[5,1-b]purin-7-yl]phenyl]ethyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} O \\ \parallel \\ N \\ O \end{array}$$
 Me 
$$\begin{array}{c} N \\ N \\ N \\ N \end{array}$$
 NHMe

RN 754225-01-9 CAPLUS

CN Benzeneacetic acid, 3-[1-methyl-4-(methylamino)-1H-pyrazolo[5,1-b]purin-7-yl]- (9CI) (CA INDEX NAME)

RN 754225-04-2 CAPLUS

CN 1H-Pyrazolo[5,1-b]purin-4-amine, N-cyclopropyl-7-(3-fluoro-4-methoxyphenyl)-1-methyl- (9CI) (CA INDEX NAME)

RN 754225-05-3 CAPLUS

CN Benzenepropanoic acid, 5-[4-(cyclopropylamino)-1-methyl-1H-pyrazolo[5,1-b]purin-7-yl]-2-fluoro- (9CI) (CA INDEX NAME)

RN 754225-06-4 CAPLUS

CN 1H-Pyrazolo[5,1-b]purin-4-amine, N-cyclopropyl-7-(3,6-dihydro-2H-pyran-4-yl)-1-methyl- (9CI) (CA INDEX NAME)

RN 754225-07-5 CAPLUS

CN 1H-Pyrazolo[5,1-b]purin-4-amine, N-cyclopropyl-7-(3,4-difluoro-5-methoxyphenyl)-1-methyl- (9CI) (CA INDEX NAME)

RN 754225-09-7 CAPLUS

CN 1H-Pyrazolo[5,1-b]purin-4-amine, N-cyclopropyl-7-(2,5-difluorophenyl)-1-methyl- (9CI) (CA INDEX NAME)

RN 754225-11-1 CAPLUS

CN 1H-Pyrazolo[5,1-b]purin-4-amine, N-cyclopropyl-7-(3,4-difluorophenyl)-1-methyl- (9CI) (CA INDEX NAME)

RN 754225-12-2 CAPLUS

CN 1H-Pyrazolo[5,1-b]purin-4-amine, N-cyclopropyl-1-methyl-7-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)

RN 754225-14-4 CAPLUS

CN 4-Morpholinecarboxamide, N-[[5-[4-(cyclopropylamino)-1-methyl-1H-pyrazolo[5,1-b]purin-7-yl]-2-fluorophenyl]methyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ &$$

RN 754225-16-6 CAPLUS

CN Benzenesulfonamide, N-[[5-[4-(cyclopropylamino)-1-methyl-1H-pyrazolo[5,1-b]purin-7-yl]-2-fluorophenyl]methyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} O \\ \parallel \\ Ph-S-NH-CH_2 \\ \parallel \\ O \\ \end{array}$$

RN 754225-18-8 CAPLUS

CN Carbamic acid, [[5-[4-(cyclopropylamino)-1-methyl-1H-pyrazolo[5,1-b]purin-7-yl]-2-fluorophenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} O & \\ MeO-C-NH-CH_2 & \\ F & \\ N &$$

RN 754225-19-9 CAPLUS

CN Benzamide, N-[[5-[4-(cyclopropylamino)-1-methyl-1H-pyrazolo[5,1-b]purin-7-yl]-2-fluorophenyl]methyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} O & Me \\ Ph-C-NH-CH_2 & Me \\ \hline F & N & N \\ \hline N & N & N \\ \hline \end{array}$$

RN 754225-20-2 CAPLUS

CN 1-Propanesulfonamide, N-[[5-[4-(cyclopropylamino)-1-methyl-1H-pyrazolo[5,1-b]purin-7-yl]-2-fluorophenyl]methyl]- (9CI) (CA INDEX NAME)

RN 754225-22-4 CAPLUS

CN Propanamide, N-[[5-[4-(cyclopropylamino)-1-methyl-1H-pyrazolo[5,1-b]purin-7-yl]-2-fluorophenyl]methyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} C & Me \\ \hline Et-C-NH-CH_2 & Me \\ \hline F & N & N \\ \hline N & N & N \\ \hline N & N & N \\ \hline \end{array}$$

RN 754225-24-6 CAPLUS

CN Carbamic acid, [[5-[4-(cyclopropylamino)-1-methyl-1H-pyrazolo[5,1-b]purin-7-yl]-2-fluorophenyl]methyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

RN 754225-26-8 CAPLUS

CN Acetamide, N-[[5-[4-(cyclopropylamino)-1-methyl-1H-pyrazolo[5,1-b]purin-7-yl]-2-fluorophenyl]methyl]-2-methoxy- (9CI) (CA INDEX NAME)

RN 754225-27-9 CAPLUS

CN Cyclopropanecarboxamide, N-[[5-[4-(cyclopropylamino)-1-methyl-1H-pyrazolo[5,1-b]purin-7-yl]-2-fluorophenyl]methyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ &$$

RN 754225-29-1 CAPLUS

CN Acetamide, N-[[5-[4-(cyclopropylamino)-1-methyl-1H-pyrazolo[5,1-b]purin-7-yl]-2-fluorophenyl]methyl]-2-(dimethylamino)- (9CI) (CA INDEX NAME)

RN 754225-31-5 CAPLUS

CN Cyclobutanecarboxamide, N-[[5-[4-(cyclopropylamino)-1-methyl-1H-pyrazolo[5,1-b]purin-7-yl]-2-fluorophenyl]methyl]- (9CI) (CA INDEX NAME)

RN 754225-33-7 CAPLUS

CN Urea, [[3-[1-methyl-4-(methylamino)-1H-pyrazolo[5,1-b]purin-7-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

RN 754225-35-9 CAPLUS

CN Benzeneacetamide, 3-[1-methyl-4-(methylamino)-1H-pyrazolo[5,1-b]purin-7-yl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)

RN 754225-36-0 CAPLUS

CN Benzeneacetamide, 3-[1-methyl-4-(methylamino)-1H-pyrazolo[5,1-b]purin-7-yl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 754225-38-2 CAPLUS

CN Benzeneacetamide, 3-[1-methyl-4-(methylamino)-1H-pyrazolo[5,1-b]purin-7-yl]-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 754225-41-7 CAPLUS

CN 1H-Pyrazolo[5,1-b]purin-4-amine, N,1,6-trimethyl-7-phenyl- (9CI) (CA INDEX NAME)

RN 754225-46-2 CAPLUS

CN Ethanol, 2-[[7-(3-bromophenyl)-1-methyl-1H-pyrazolo[5,1-b]purin-4-yl]amino]- (9CI) (CA INDEX NAME)

RN

754225-47-3 CAPLUS 1-Propanol, 3-[[7-(3-bromophenyl)-1-methyl-1H-pyrazolo[5,1-b]purin-4-CN yl]amino] - (9CI) (CA INDEX NAME)

754225-48-4 CAPLUS RN

Glycine, N-[7-(3-bromophenyl)-1-methyl-1H-pyrazolo[5,1-b]purin-4-yl]-CN(CA INDEX NAME)

RN 754225-49-5 CAPLUS

1H-Pyrazolo[5,1-b]purin-4-amine, 7-(3-bromophenyl)-1-methyl-N-4-CN morpholinyl- (9CI) (CA INDEX NAME)

RN 754225-50-8 CAPLUS

CN 1H-Pyrazolo[5,1-b]purin-4-amine, 7-(3-bromophenyl)-N-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-1-methyl- (9CI) (CA INDEX NAME)

RN 754225-51-9 CAPLUS

CN Benzonitrile, 3-[1-methyl-4-(4-morpholinylamino)-1H-pyrazolo[5,1-b]purin-7-yl]- (9CI) (CA INDEX NAME)

RN 754225-53-1 CAPLUS

CN Benzonitrile, 3-[4-[(3-hydroxypropyl)amino]-1-methyl-1H-pyrazolo[5,1-b]purin-7-yl]- (9CI) (CA INDEX NAME)

NC NH- (
$$CH_2$$
) 3-OH

RN 754225-54-2 CAPLUS

CN Benzonitrile, 3-[4-[(2-hydroxyethyl)amino]-1-methyl-1H-pyrazolo[5,1-b]purin-7-yl]- (9CI) (CA INDEX NAME)

RN 754225-56-4 CAPLUS

CN Benzonitrile, 3-[4-[(2,3-dihydroxypropyl)amino]-1-methyl-1H-pyrazolo[5,1-b]purin-7-yl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\ N & \\ N & & \\ N & \\$$

RN 754225-58-6 CAPLUS

CN Acetamide, N-[[3-[1-methyl-4-(methylamino)-1H-pyrazolo[5,1-b]purin-7-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

RN 754225-60-0 CAPLUS

CN Acetic acid, [{[3-[1-methyl-4-(methylamino)-1H-pyrazolo[5,1-b]purin-7-yl]phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{Me} \\ & \parallel & \parallel \\ & \parallel & \parallel \\ & \text{EtO-} \text{ C--} \text{ C--} \text{ NH--} \text{ CH}_2 \\ & & N \\ & N \\ & & N \\ & & N \\ & & N \\ & N$$

RN 754225-62-2 CAPLUS

CN Butanoic acid, 4-[[[3-[1-methyl-4-(methylamino)-1H-pyrazolo[5,1-b]purin-7-yl]phenyl]methyl]amino]-4-oxo-(9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & & \\ & & & \\ \text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{C}-\text{NH}-\text{CH}_2 \\ & & & \\ & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & & & \\ & & & \\ & & &$$

RN 754225-63-3 CAPLUS

CN Urea, N-(1-methylethyl)-N'-[[3-[1-methyl-4-(methylamino)-1H-pyrazolo[5,1-b]purin-7-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

RN 754225-65-5 CAPLUS

CN Methanesulfonamide, N-[[3-[1-methyl-4-(methylamino)-1H-pyrazolo[5,1-b]purin-7-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

RN 754225-66-6 CAPLUS

CN Carbamic acid, [[3-[1-methyl-4-(methylamino)-1H-pyrazolo[5,1-b]purin-7-yl]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

RN 754225-68-8 CAPLUS
CN 1H-Pyrazolo[5,1-b]purin-4-amine, 7-[3-(1-aminoethyl)phenyl]-N,1-dimethyl(9CI) (CA INDEX NAME)

RN 754225-70-2 CAPLUS
CN Methanone, [3-[1-methyl-4-(methylamino)-1H-pyrazolo[5,1-b]purin-7-

yl]phenyl]phenyl- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\$$

RN 754225-71-3 CAPLUS
CN 1H-Pyrazolo[5,1-b]purin-4-amine, 7-[3-[(dimethylamino)methyl]phenyl]-N,1dimethyl- (9CI) (CA INDEX NAME)

$$Me_2N-CH_2$$
 $N$ 
 $N$ 
 $N$ 
 $N$ 
 $N$ 
 $N$ 

RN

754225-72-4 CAPLUS
Benzamide, 3-[1-methyl-4-(methylamino)-1H-pyrazolo[5,1-b]purin-7-yl]-CN (CA INDEX NAME)

RN 754225-73-5 CAPLUS

Ethanol, 2-[[1-methyl-7-(2-phenoxyethoxy)-1H-pyrazolo[5,1-b]purin-4-CN yl]amino] - (9CI) (CA INDEX NAME)

754225-74-6 CAPLUS RN

CN 1H-Pyrazolo[5,1-b]purin-4-amine, 7-[(3-aminophenyl)ethynyl]-N,1-dimethyl-(9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{Me} \\ & \text{N} \\ & \text{N} \\ & \text{N} \\ & \text{N} \\ & \text{NHMe} \\ \end{array}$$

754225-76-8 CAPLUS RN

Ethanol, 2-[[7-[3-(aminomethyl)phenyl]-1-methyl-1H-pyrazolo[5,1-b]purin-4-yl]amino]- (9CI) (CA INDEX NAME) CN

RN 754225-78-0 CAPLUS

CN Acetamide, N-[[3-[4-[(2-hydroxyethyl)amino]-1-methyl-1H-pyrazolo[5,1-b]purin-7-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

RN 754225-80-4 CAPLUS

CN Acetamide, N-[[3-[4-[[2-(acetyloxy)ethyl]amino]-1-methyl-1H-pyrazolo[5,1-b]purin-7-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)

IT 754226-07-8P 754226-09-0P 754226-30-7P

754226-37-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrazolopurine-based tricyclic compds. for the treatment of inflammatory and immune diseases)

RN 754226-07-8 CAPLUS

CN Methanesulfonic acid, trifluoro-, 1-methyl-4-(methylamino)-1H-pyrazolo[5,1-b]purin-7-yl ester (9CI) (CA INDEX NAME)

RN 754226-09-0 CAPLUS

CN Methanesulfonic acid, trifluoro-, 4-(cyclopropylamino)-1-methyl-1H-pyrazolo[5,1-b]purin-7-yl ester (9CI) (CA INDEX NAME)

RN 754226-30-7 CAPLUS

CN Benzenepropanoic acid, 3-[4-(cyclopropylamino)-1-methyl-1H-pyrazolo[5,1-b]purin-7-yl]-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & & \\ & & & \\ & &$$

RN 754226-37-4 CAPLUS

CN Benzenepropanoic acid, 5-[4-(cyclopropylamino)-1-methyl-1H-pyrazolo[5,1-b]purin-7-yl]-2-fluoro-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c} O \\ \parallel \\ MeO-C-CH_2-CH_2 \\ \hline F \\ N \\ N \\ N \\ N \\ NH \\ \end{array}$$